| Nov 20 |
PMV Pharmaceuticals files for $200M mixed shelf offering
|
| Nov 7 |
PMV Pharmaceuticals GAAP EPS of -$0.37 misses by $0.02
|
| Nov 7 |
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
|
| Oct 23 |
US Penny Stocks To Consider In October 2024
|
| Oct 23 |
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
|
| Aug 9 |
PMV Pharmaceuticals GAAP EPS of -$0.02 beats by $0.32
|
| Aug 8 |
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
|
| Jun 3 |
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
|
| May 30 |
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
|
| May 29 |
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
|
